Lasofoxifene

Generic Name: Lasofoxifene

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₃₁NO_₂

CAS Number: 180916-16-9

Unique Ingredient Identifier: 337G83N988

Background: Lasofoxifene is a non-steroidal 3rd generation selective estrogen receptor modulator (SERM) that selectively binds to both ERα and ERβ with high affinity. It is a naphthalene derivative marketed for prevention and treatment of osteoporosis and for the treatment of vaginal atrophy. It was initially developed as Oporia by Pfizer as a treatment for postmenopaus...

Indication: Investigated for use/treatment in postmenopausal osteoporosis to reduce the risk of both vertebral and novertebral fractures, as well as address other postmenopausal conditions, including reduction in risk of breast cancer and treatment of vulvar and vaginal atrophy (VVA)

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Phase 2

Active, not recruiting

Conditions: Locally Advanced or Metastatic Breast Cancer

Interventions: Drug: Lasofoxifene
Drug: Fulvestrant

First Posted Date: 2018-12-19

Last Posted Date: 2024-04-18

Lead Sponsor: Sermonix Pharmaceuticals Inc.

Target Recruit Count: 100

Registration Number: NCT03781063

Locations: 🇺🇸
Rocky Mountain Cancer Centers, Longmont, Colorado, United States
🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
The Ohio State University - Comprehensive Cancer Center, Columbus, Ohio, United States

and more 48 locations

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Phase 2

Recruiting

Conditions: HER2-negative Breast Cancer
Hormone Receptor Positive Tumor
Angiosarcoma
TNBC - Triple-Negative Breast Cancer
Breast Neoplasms
Breast Tumors
HER2-positive Breast Cancer
Hormone Receptor Negative Tumor
Breast Cancer
Early-stage Breast Cancer

Interventions: Drug: Standard Therapy
Drug: AMG 386 with or without Trastuzumab
Drug: AMG 479 (Ganitumab) plus Metformin
Drug: MK-2206 with or without Trastuzumab
Drug: T-DM1 and Pertuzumab
Drug: Pertuzumab and Trastuzumab
Drug: Ganetespib
Drug: ABT-888
Drug: Neratinib
Drug: PLX3397
Drug: Pembrolizumab - 4 cycle
Drug: Talazoparib plus Irinotecan
Drug: Patritumab and Trastuzumab
Drug: Pembrolizumab - 8 cycle
Drug: SGN-LIV1A
Drug: Durvalumab plus Olaparib
Drug: SD-101 + Pembrolizumab
Drug: Tucatinib plus trastuzumab and pertuzumab
Drug: Cemiplimab
Drug: Cemiplimab plus REGN3767
Drug: Trilaciclib with or without trastuzumab + pertuzumab
Drug: SYD985 ([vic-]trastuzumab duocarmazine)
Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab
Drug: Dan222 + Niraparib
Drug: Sarilumab + Cemiplimab + Paclitaxel
Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab
Drug: Amcenestrant
Drug: Amcenestrant + Abemaciclib
Drug: Amcenestrant + Letrozole
Drug: ARX788
Drug: ARX788 + Cemiplimab
Drug: VV1 + Cemiplimab
Drug: Datopotamab deruxtecan
Drug: Datopotamab deruxtecan + Durvalumab
Drug: Zanidatamab
Drug: Lasofoxifene
Drug: Z-endoxifen
Drug: ARV-471
Drug: ARV-471 + Letrozole
Drug: ARV-471 + Abemaciclib
Drug: Endoxifen + Abemaciclib
Drug: Rilvegostomig + TDXd
Drug: AMG 386 and Trastuzumab

First Posted Date: 2010-01-05

Last Posted Date: 2024-10-22

Lead Sponsor: QuantumLeap Healthcare Collaborative

Target Recruit Count: 5000

Registration Number: NCT01042379

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
University of Texas, Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
University of Kansas, Westwood, Kansas, United States

and more 33 locations

The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation

Phase 2

Completed

Conditions: Bone Loss

Interventions: Other: Placebo
Drug: Lasofoxifene

First Posted Date: 2008-05-07

Last Posted Date: 2011-08-10

Lead Sponsor: Ligand Pharmaceuticals

Target Recruit Count: 51

Registration Number: NCT00674453

Locations: 🇬🇧
Pfizer Investigational Site, Sheffield, United Kingdom

Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss

Phase 3

Completed

Conditions: Osteoporosis

Interventions: Drug: raloxifene
Drug: lasofoxifene
Drug: Placebo

First Posted Date: 2005-09-13

Last Posted Date: 2011-08-12

Lead Sponsor: Ligand Pharmaceuticals

Target Recruit Count: 540

Registration Number: NCT00163137

Locations: 🇺🇸
Pfizer Investigational Site, Seattle, Washington, United States

Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose Evaluation

Phase 2

Completed

Conditions: Osteoporosis

Interventions: Drug: Lasofoxifene
Drug: Placebo

First Posted Date: 2005-09-02

Last Posted Date: 2011-08-10

Lead Sponsor: Ligand Pharmaceuticals

Target Recruit Count: 497

Registration Number: NCT00143273

Locations: Pfizer Investigational Site

Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)

Phase 3

Completed

Conditions: Osteoporosis

Interventions: Other: placebo
Drug: lasofoxifene

First Posted Date: 2005-09-01

Last Posted Date: 2011-08-15

Lead Sponsor: Ligand Pharmaceuticals

Target Recruit Count: 8556

Registration Number: NCT00141323

Locations: 🇬🇧
Pfizer Investigational Site, Northwood, Middlesex, United Kingdom

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy